Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma

Sophie Cottin, Virginie Doyen, Charles Pilette

Open source

DOI
10.3389/fmed.2023.1129300
Published
2023-03-22
Container
Frontiers in Medicine
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fmed.2023.1129300,
  title = {Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma},
  author = {Sophie Cottin and Virginie Doyen and Charles Pilette},
  year = {2023},
  journal = {Frontiers in Medicine},
  doi = {10.3389/fmed.2023.1129300},
  url = {https://doi.org/10.3389/fmed.2023.1129300}
}

RIS

TY  - JOUR
TI  - Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma
AU  - Sophie Cottin
AU  - Virginie Doyen
AU  - Charles Pilette
PY  - 2023
JO  - Frontiers in Medicine
DO  - 10.3389/fmed.2023.1129300
UR  - https://doi.org/10.3389/fmed.2023.1129300
ER  - 

APA

Cottin, S., Doyen, V., & Pilette, C. (2023). Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma. Frontiers in Medicine. https://doi.org/10.3389/fmed.2023.1129300

Source records